Eli Lilly 2012 Annual Report Download - page 43

31
The following table summarizes our revenue activity in 2011 compared with 2010:
Year Ended Year Ended
December 31, 2011 December 31,
2010 Percent Change from
Product U.S.(1) Outside U.S. Total Total 2010
(Dollars in millions)
Zyprexa . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2,165.3 $ 2,456.7 $ 4,622.0 $ 5,026.4 (8)
Cymbalta. . . . . . . . . . . . . . . . . . . . . . . . . 3,173.4 988.4 4,161.8 3,459.2 20
Alimta . . . . . . . . . . . . . . . . . . . . . . . . . . . 994.6 1,466.5 2,461.1 2,208.6 11
Humalog . . . . . . . . . . . . . . . . . . . . . . . . . 1,398.9 968.7 2,367.6 2,054.2 15
Cialis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 704.5 1,171.1 1,875.6 1,699.4 10
Humulin. . . . . . . . . . . . . . . . . . . . . . . . . . 588.1 660.7 1,248.8 1,088.9 15
Evista. . . . . . . . . . . . . . . . . . . . . . . . . . . . 707.5 359.4 1,066.9 1,024.4 4
Forteo . . . . . . . . . . . . . . . . . . . . . . . . . . . 453.1 496.7 949.8 830.1 14
Strattera . . . . . . . . . . . . . . . . . . . . . . . . . 392.2 227.9 620.1 576.7 8
Gemzar . . . . . . . . . . . . . . . . . . . . . . . . . . 70.6 381.5 452.1 1,149.4 (61)
Other pharmaceutical products . . . . . . 879.4 1,221.0 2,100.4 1,933.5 9
Animal health products . . . . . . . . . . . . . 896.8 781.8 1,678.6 1,391.4 21
Total net product sales . . . . . . . . . . . 12,424.4 11,180.4 23,604.8 22,442.2 5
Collaboration and other revenue(2) . . . . 552.8 128.9 681.7 633.8 8
Total revenue . . . . . . . . . . . . . . . . . . . $ 12,977.2 $ 11,309.3 $ 24,286.5 $ 23,076.0 5
1 U.S. revenue includes revenue in Puerto Rico.
2 Collaboration and other revenue consists primarily of royalties for Erbitux and revenue associated with exenatide in the United States.
Sales of Zyprexa decreased 13 percent in the U.S., due to the loss of patent exclusivity in the U.S. on October
23, 2011. Despite a decline in demand for branded Zyprexa, U.S. volume increased in 2011 primarily as a
result of sales of authorized olanzapine in connection with our six-month agreement with Prasco
Laboratories. This volume increase was more than offset by significant price reductions attributable both to
branded Zyprexa and authorized olanzapine. Sales outside the U.S. decreased 3 percent, driven primarily by
the loss of patent exclusivity throughout most major markets outside of Japan during 2011, partially offset by
the favorable impact of foreign exchange rates and increased demand in Japan.
Sales of Cymbalta increased 14 percent in the U.S., driven primarily by increased demand and higher prices.
Sales outside the U.S. increased 44 percent, driven primarily by increased demand and, to a lesser extent, the
favorable impact of foreign exchange rates.
Sales of Alimta increased 4 percent in the U.S., due primarily to higher prices and increased demand. Sales
outside the U.S. increased 17 percent, due to increased demand and, to a lesser extent, the favorable impact
of foreign exchange rates.
Sales of Humalog increased 14 percent in the U.S., due to increased demand and, to a lesser extent, higher
prices. Sales outside the U.S. increased 16 percent, driven by increased demand and, to a lesser extent, the
favorable impact of foreign exchange rates.
Sales of Cialis increased 7 percent in the U.S., primarily due to higher prices. Sales outside the U.S. increased
12 percent, driven by increased demand, the favorable impact of foreign exchange rates, and higher prices.
Sales of Humulin increased 25 percent in the U.S., driven primarily by higher prices for Humulin and
increased demand attributable to Humulin ReliOn. Sales outside the U.S. increased 7 percent, due to
increased demand and the favorable impact of foreign exchange rates, partially offset by lower prices.